Previous Close | 23.76 |
Open | 24.31 |
Bid | 23.71 x 100 |
Ask | 23.74 x 100 |
Day's Range | 23.58 - 24.67 |
52 Week Range | 18.61 - 29.35 |
Volume | |
Avg. Volume | 795,945 |
Market Cap | 1.813B |
Beta (5Y Monthly) | 1.64 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.93 |
Earnings Date | Aug 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.00 |
Veracyte Inc specializes in genomic diagnostics and is focused on providing answers that enable physicians to make more informed decisions early in patient care. Over the past year, Jens Holstein's trading activity includes the sale of 5,000 shares and no purchases. The broader insider transaction history for Veracyte Inc shows a pattern of 9 insider sales and no insider buys over the same period.
SOUTH SAN FRANCISCO, Calif., July 17, 2024--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of market on Tuesday, August 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.